Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
C4X Discovery
C4X Discovery
Activities:
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Drug Delivery
C4XD signs $402 million licence with AstraZeneca
C4XD is eligible to receive upfront and pre-clinical payments of $16 million, plus development and commercial milestones, and tiered mid-single digit royalties
Research & Development
C4XD receives first milestone payment of €3 million from Sanofi
€3 million milestone payment triggered by preclinical progression in oral IL-17A inhibitor programme
Research & Development
C4X Discovery buys genetic platform provider Adorial for £1.7m
Adorial's mathematical tool Taxonomy3 has the potential to increase small molecule drug development success
Research & Development
C4X Discovery appoints Piers Morgan as Chief Executive
Succeeds Sam Williams who returns to Non-Executive Director role
Research & Development
UK biotechs win Biomedical Catalyst funding of almost £100m
Thirty-three UK companies have received business-led awards
Subscribe now